Tvardi Therapeutics
TVRD
168 hedge funds and large institutions have $703M invested in Tvardi Therapeutics in 2021 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 44 increasing their positions, 48 reducing their positions, and 17 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
157% more call options, than puts
Call options by funds: $52.7M | Put options by funds: $20.5M
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
42% more capital invested
Capital invested by funds: $494M → $703M (+$209M)
8% more funds holding
Funds holding: 156 → 168 (+12)
0.02% less ownership
Funds ownership: 1.82% → 1.8% (-0.02%)
8% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.42M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$4.57M |
| 3 |
PCM
Penserra Capital Management
Orinda,
California
|
+$3.76M |
| 4 |
Two Sigma Investments
New York
|
+$3.52M |
| 5 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
-$11.4M |
| 2 |
First Manhattan
New York
|
-$9.29M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$6.57M |
| 4 |
RCP
Rho Capital Partners
New York
|
-$4.75M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$3.69M |
TVRD Hedge Fund Activity: Q1 2021 in Review
168 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2021, worth a combined $703M — up 42% from $494M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TVRD positions and 17 closed out — a net gain of 14 holders — while 44 added to existing stakes and 48 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $5.42M. The largest seller was Carmignac Gestion, cutting an estimated $11.4M.
- 168 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2021, up from 156 in Q4 2020.
- Funds reported $703M of Tvardi Therapeutics stock for Q1 2021, up 42% quarter-over-quarter.
- 31 funds opened new Tvardi Therapeutics positions in Q1 2021 and 17 closed out, a net change of +14 holders.
- The largest Tvardi Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $5.42M added.
- The largest Tvardi Therapeutics seller in Q1 2021 was Carmignac Gestion, an estimated $11.4M sold.
Based on aggregated 13F filings for Q1 2021.